Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Gammill

Internal Medicine Enterprise, AL Doctor of Osteopathy

NPI 1437199908 CMS profile 110690

101 E Brunson St, Suite 200, Enterprise, AL 36330

Open in the dashboard

General payments

$13,397

984 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Gammill of Enterprise, AL is reported in the CMS Open Payments database as having received $13,397 across 984 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,545 95
2024 General $1,554 110
2023 General $1,807 129
2022 General $1,947 141
2021 General $2,108 154
2020 General $2,073 138
2019 General $2,363 217

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Gammill
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to William Gammill were reported at $1,545. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year William Gammill Internal Medicine median Middle half National median
2019 $2,363 $159 $48–$570 $163
2020 $2,073 $119 $33–$402 $114
2021 $2,108 $135 $37–$521 $132
2022 $1,947 $141 $42–$496 $149
2023 $1,807 $149 $45–$519 $160
2024 $1,554 $154 $47–$537 $164
2025 $1,545 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,374 104 payments
  2. GlaxoSmithKline, LLC. $1,238 97 payments
  3. Novo Nordisk Inc $1,197 112 payments
  4. Janssen Pharmaceuticals, Inc $1,093 73 payments
  5. Lilly USA, LLC $1,001 100 payments
  6. AstraZeneca Pharmaceuticals LP $923 56 payments
  7. Pfizer Inc. $920 71 payments
  8. Amgen Inc. $736 53 payments
  9. Allergan Inc. $518 46 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $440 39 payments
  11. Other $3,957 233 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,363 979 payments
  2. Education $35 5 payments
Products named General payments · program years 2019–2025
  1. XARELTO $1,077 70 payments
  2. Ozempic $834 92 payments
  3. RYBELSUS $812 83 payments
  4. TRELEGY ELLIPTA $796 56 payments
  5. VRAYLAR $765 59 payments
  6. MOUNJARO $626 58 payments
  7. NURTEC ODT $479 32 payments
  8. FARXIGA $424 24 payments
  9. Repatha $395 29 payments
  10. Korlym $385 15 payments
  11. Other $11,670 934 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 214 drugs

Part D claims

16,945

Median for Internal Medicine: 777

Drug cost

$1,865,820

Median for Internal Medicine: $73,373

Branded share of claims

25.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 305 $283,552
Trulicity Dulaglutide Brand 163 $176,629
Mounjaro Tirzepatide Brand 159 $169,101
Eliquis Apixaban Brand 156 $115,913
Ozempic Semaglutide Brand 79 $97,953
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 110 $94,707
Xarelto Rivaroxaban Brand 118 $91,282
Synjardy Xr Empagliflozin/Metformin Hcl Brand 55 $47,151
Vraylar Cariprazine Hcl Brand 31 $44,803
Linzess Linaclotide Brand 58 $41,762

The 10 drugs with the highest cost, of 214 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 125 billing codes

Paid by Medicare

$240,909

Of which drugs: $465

Medicare patients

510

Average age 75

Services billed

12,360

274 women, 236 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 37%
Chronic kidney disease 35%
Ischemic heart disease 29%
Depression 25%
Atrial fibrillation 21%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 33 2,734 $236
Injection, methylprednisolone acetate, 80 mg J1040 Office 22 23 $108
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 20 68 $61
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 43 397 $29
Injection, ceftriaxone sodium, per 250 mg J0696 Office 11 52 $14

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
$156 159 —
UBRELVY
$139 — —
VRAYLAR
$117 31 —
AIRSUPRA
$117 — —
REXULTI
$92 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

984 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record